Primary and secondary long-term prophylaxis of thromboembolism in outpatients with the low-molecular-weight heparin Kabi 2165.
Bleeding episodes and other side effects may complicate the treatment with oral anticoagulants. We report on the results of 66 patients who were treated with a low molecular weight heparin fraction for up to 19 months. The data of the study demonstrate the effective long-term anticoagulation with low-molecular-weight heparin and the reduced incidence of hemorrhages compared with conventional anticoagulants. Thus, low-molecular-weight heparin may be effectively and safely used for long-term anticoagulation in patients with bleeding problems on conventional anticoagulants.
Harenberg
J
J
Medical Clinic I, Klinikum Mannheim, University of Heidelberg, FRG.
Leber
G
G
Raedsch
R
R
Zimmermann
R
R
Schwarz
F
F
Kübler
W
W
D002986:Clinical Trials as Topic; D015951:Factor Xa; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D015842:Serine Proteinase Inhibitors; D013923:Thromboembolism / Q000517:prevention & control*
D006495:Heparin, Low-Molecular-Weight; D015842:Serine Proteinase Inhibitors; D015951:Factor Xa